The cobas Mass Spec solution Ionify reagent portfolio now covers therapeutic drug monitoring for immunosuppressants and antibiotics
LNK01006 is designed to deliver potent, selective inhibition of TYK2-mediated cytokine signaling with central nervous system exposure
At the trial’s pre-specified interim analysis, giredestrant achieved a hazard ratio of 0.70, marking a statistically significant improvement in invasive disease-free survival
This partnership strengthens LMS as a leading CDMO supplier of peptide materials for both innovator and generic markets
The Phase 2 study tested two dose levels of pumitamig alongside four standard chemotherapy regimens across first
Zyrifa is indicated for patients with bone metastases stemming from a wide range of solid tumors
This strategic investment aims to bolster the company's position as a global leader in Vitamin D3 manufacturing
Dr Reddy’s will pay Immutep US$ 20 million upfront and could deliver as much as US$ 349.5 million in regulatory and commercial milestones
The collaboration will establish the MUMPMP–Agilent BioDiscovery Hub
The company also revealed that MK-2214 has received Fast Track Designation from the U.S. Food and Drug Administration
Subscribe To Our Newsletter & Stay Updated
